First FDA Approval for a Treatment Directly Targeting Demodex Mites

A panel of eye care experts, consisting of a including an ophthalmic surgeon, ophthalmologist, optometrist (OD), payer, ophthalmic assistant, go in-depth to discuss lotilaner, the first FDA-approved treatment for demodex blepharitis. The full panel comprised:

Marjan Farid, MD, Gavin Herbert Eye Institute and the University of California, Irvine

Eric D. Donnenfeld, MD, Ophthalmic Consultants of Long Island Vision

Paul Karpecki, OD, of Kentucky Eye Institute

Jeffrey Dunn, PharmD, MBA, of Cooperative Benefits Group in Draper, Utah

Derrick Sterling, COA, OSC, of KTND Ophthalmology Associates in Philadelphia

Learn how this therapy works - from the science behind it - to real-world evidence supporting its use in this population.